Physician profile
Jonathan Buck
NPI 1487017646
$4,761.36
in general payments reported to CMS, 2019-2025
37 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.75 · 2020: $42.88 · 2021: $107 · 2022: $490 · 2023: $1,080 · 2024: $1,655 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,042.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,828.49 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $493.36 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $376.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $252.04 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $165.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.66 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $152.97 | 2021-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $149.77 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $136.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.25 | 2019-2024 | Jardiance, Synjardy |
| Astellas Pharma US INC | $89.64 | 2024-2025 | Veozah |
| Gilead Sciences, INC. | $84.25 | 2024-2025 | |
| Eisai INC. | $78.90 | 2024-2025 | |
| Exact Sciences Corporation | $77.98 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $52.79 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.82 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Axsome Therapeutics, INC. | $50.67 | 2024-2025 | Auvelity, Sunosi |
| Shield Therapeutics INC | $47.75 | 2023-2024 | Accrufer |
| Abbott Laboratories | $44.79 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $40.99 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $32.81 | 2020-2021 | |
| Pulmonx Corporation | $29.88 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Amarin Pharma, INC. | $22.34 | 2021 | |
| Neurelis, INC. | $21.93 | 2024 | Valtoco |
| Corcept Therapeutics | $21.56 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.92 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $20.58 | 2024 | Injectafer |
| Allergan, INC. | $18.71 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.08 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $16.06 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2022 | |
| Tactile Systems Technology INC | $14.58 | 2023 | Entre Plus, Flexitouch Plus |
| Inspire Medical Systems, INC. | $14.49 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $14.26 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $13.59 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $12.34 | 2020 | |
| Dynavax Technologies Corporation | $7.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.